{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T23:12:55Z","timestamp":1788649975276,"version":"build-2803163510"},"reference-count":125,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T00:00:00Z","timestamp":1651190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T00:00:00Z","timestamp":1651190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s00393-022-01205-5","type":"journal-article","created":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T13:18:28Z","timestamp":1651238308000},"page":"233-245","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Dermatomyositis und juvenile Dermatomyositis","Dermatomyositis and juvenile dermatomyositis"],"prefix":"10.1007","volume":"82","author":[{"given":"Frank","family":"Dressler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,29]]},"reference":[{"issue":"7","key":"1205_CR1","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s00393-006-0109-5","volume":"65","author":"F Dressler","year":"2006","unstructured":"Dressler\u00a0F, Huppertz\u00a0HI (2006) Juvenile dermatomyositis. Z\u00a0Rheumatol 65(7):587\u2013594","journal-title":"Z Rheumatol"},{"issue":"7","key":"1205_CR2","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/gene.2015.28","volume":"16","author":"FW Miller","year":"2015","unstructured":"Miller\u00a0FW et al (2015) Genome-wide association study identifies HLA 8.1 ancestral haplotype alleles as major genetic risk factors for myositis phenotypes. Genes Immun 16(7):470\u2013480","journal-title":"Genes Immun"},{"issue":"3","key":"1205_CR3","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1002\/art.11122","volume":"49","author":"EP Mendez","year":"2003","unstructured":"Mendez\u00a0EP et\u00a0al (2003) US incidence of juvenile dermatomyositis, 1995\u20131998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum 49(3):300\u2013305","journal-title":"Arthritis Rheum"},{"issue":"8","key":"1205_CR4","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1093\/rheumatology\/34.8.732","volume":"34","author":"DP Symmons","year":"1995","unstructured":"Symmons\u00a0DP, Sills\u00a0JA, Davis\u00a0SM (1995) The incidence of juvenile dermatomyositis: results from a\u00a0nation-wide study. Br J Rheumatol 34(8):732\u2013736","journal-title":"Br J Rheumatol"},{"issue":"8","key":"1205_CR5","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1136\/annrheumdis-2013-205127","volume":"74","author":"C Dobloug","year":"2015","unstructured":"Dobloug\u00a0C et\u00a0al (2015) Prevalence and clinical characteristics of adult polymyositis and dermatomyositis; data from a\u00a0large and unselected Norwegian cohort. Ann Rheum Dis 74(8):1551\u20131556","journal-title":"Ann Rheum Dis"},{"key":"1205_CR6","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1740-2557-3-2","volume":"3","author":"K Nagaraju","year":"2006","unstructured":"Nagaraju\u00a0K et\u00a0al (2006) Endothelial cell activation and neovascularization are prominent in dermatomyositis. J\u00a0Autoimmune Dis 3:2","journal-title":"J Autoimmune Dis"},{"issue":"10","key":"1205_CR7","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1002\/1529-0131(200010)43:10<2368::AID-ANR26>3.0.CO;2-8","volume":"43","author":"LM Pachman","year":"2000","unstructured":"Pachman\u00a0LM et al (2000) TNFalpha-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications. Arthritis Rheum 43(10):2368\u20132377","journal-title":"Arthritis Rheum"},{"issue":"12","key":"1205_CR8","doi-asserted-by":"publisher","first-page":"3941","DOI":"10.1002\/art.24039","volume":"58","author":"G Mamyrova","year":"2008","unstructured":"Mamyrova\u00a0G et\u00a0al (2008) Cytokine gene polymorphisms as risk and severity factors for juvenile dermatomyositis. Arthritis Rheum 58(12):3941\u20133950","journal-title":"Arthritis Rheum"},{"issue":"5","key":"1205_CR9","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s11926-018-0733-5","volume":"20","author":"PW Wolstencroft","year":"2018","unstructured":"Wolstencroft\u00a0PW, Fiorentino\u00a0DF (2018) Dermatomyositis clinical and pathological phenotypes associated with myositis-specific autoantibodies. Curr Rheumatol Rep 20(5):28","journal-title":"Curr Rheumatol Rep"},{"issue":"3","key":"1205_CR10","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s11926-010-0100-7","volume":"12","author":"JP Callen","year":"2010","unstructured":"Callen\u00a0JP (2010) Cutaneous manifestations of dermatomyositis and their management. Curr Rheumatol Rep 12(3):192\u2013197","journal-title":"Curr Rheumatol Rep"},{"issue":"5","key":"1205_CR11","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1517\/14656566.5.5.1083","volume":"5","author":"RD Sontheimer","year":"2004","unstructured":"Sontheimer\u00a0RD (2004) The management of dermatomyositis: current treatment options. Expert Opin Pharmacother 5(5):1083\u20131099","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"1205_CR12","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.semarthrit.2017.06.001","volume":"47","author":"C Bertolazzi","year":"2017","unstructured":"Bertolazzi\u00a0C et\u00a0al (2017) State of the art on nailfold capillaroscopy in dermatomyositis and polymyositis. Semin Arthritis Rheum 47(3):432\u2013444","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"1205_CR13","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1097\/MD.0b013e31816bc604","volume":"87","author":"A Bingham","year":"2008","unstructured":"Bingham\u00a0A et al (2008) Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a\u00a0gradient of severity. Medicine 87(2):70\u201386","journal-title":"Medicine"},{"issue":"2","key":"1205_CR14","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1210\/jc.2005-1220","volume":"91","author":"EA Oral","year":"2006","unstructured":"Oral\u00a0EA et\u00a0al (2006) Leptin replacement therapy modulates circulating lymphocyte subsets and cytokine responsiveness in severe lipodystrophy. J\u00a0Clin Endocrinol Metab 91(2):621\u2013628","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"1205_CR15","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s11926-014-0467-y","volume":"16","author":"MF Hoeltzel","year":"2014","unstructured":"Hoeltzel\u00a0MF et\u00a0al (2014) The presentation, assessment, pathogenesis, and treatment of calcinosis in juvenile dermatomyositis. Curr Rheumatol Rep 16(12):467","journal-title":"Curr Rheumatol Rep"},{"issue":"4","key":"1205_CR16","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1001\/archdermatol.2011.2052","volume":"148","author":"SJ Balin","year":"2012","unstructured":"Balin\u00a0SJ et\u00a0al (2012) Calcinosis cutis occurring in association with autoimmune connective tissue disease: the Mayo Clinic experience with 78\u00a0patients, 1996\u20132009. Arch Dermatol 148(4):455\u2013462","journal-title":"Arch Dermatol"},{"issue":"2","key":"1205_CR17","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.semarthrit.2016.03.011","volume":"46","author":"E Trallero-Araguas","year":"2016","unstructured":"Trallero-Araguas\u00a0E et al (2016) Clinical manifestations and long-term outcome of anti-Jo1 antisynthetase patients in a\u00a0large cohort of Spanish patients from the GEAS-IIM group. Semin Arthritis Rheum 46(2):225\u2013231","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"1205_CR18","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1002\/art.22782","volume":"57","author":"G Mamyrova","year":"2007","unstructured":"Mamyrova\u00a0G et al (2007) Late-onset gastrointestinal pain in juvenile dermatomyositis as a\u00a0manifestation of ischemic ulceration from chronic endarteropathy. Arthritis Rheum 57(5):881\u2013884","journal-title":"Arthritis Rheum"},{"issue":"8","key":"1205_CR19","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1093\/rheumatology\/36.8.912","volume":"36","author":"Y See","year":"1997","unstructured":"See\u00a0Y et\u00a0al (1997) Severe juvenile dermatomyositis complicated by pancreatitis. Br J Rheumatol 36(8):912\u2013916","journal-title":"Br J Rheumatol"},{"issue":"4","key":"1205_CR20","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/00005792-196607000-00001","volume":"45","author":"BQ Banker","year":"1966","unstructured":"Banker\u00a0BQ, Victor\u00a0M (1966) Dermatomyositis (systemic angiopathy) of childhood. Medicine 45(4):261\u2013289","journal-title":"Medicine"},{"issue":"3","key":"1205_CR21","first-page":"499","volume":"20","author":"E Pasquier","year":"1993","unstructured":"Pasquier\u00a0E, Wattiaux\u00a0MJ, Peigney\u00a0N (1993) First case of pneumatosis cystoides intestinalis in adult dermatomyositis. J\u00a0Rheumatol 20(3):499\u2013503","journal-title":"J Rheumatol"},{"key":"1205_CR22","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/1749-7922-9-48","volume":"9","author":"R Villa","year":"2014","unstructured":"Villa\u00a0R et\u00a0al (2014) Successful open abdomen treatment for multiple ischemic duodenal perforated ulcers in dermatomyositis. World J Emerg Surg 9:48","journal-title":"World J Emerg Surg"},{"key":"1205_CR23","doi-asserted-by":"publisher","first-page":"bcr2015213460","DOI":"10.1136\/bcr-2015-213460","volume":"2016","author":"N Kibbi","year":"2016","unstructured":"Kibbi\u00a0N, Bekui\u00a0A, Buckley\u00a0LM (2016) Colonic vasculopathy and perforation in the initial presentation of adult dermatomyositis in a patient with improving muscle weakness. BMJ Case Rep 2016:bcr2015213460","journal-title":"BMJ Case Rep"},{"issue":"4","key":"1205_CR24","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1097\/MD.0b013e31829d08f9","volume":"92","author":"LG Rider","year":"2013","unstructured":"Rider\u00a0LG et\u00a0al (2013) The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine 92(4):223\u2013243","journal-title":"Medicine"},{"issue":"3","key":"1205_CR25","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3899\/jrheum.160682","volume":"44","author":"S Moghadam-Kia","year":"2017","unstructured":"Moghadam-Kia\u00a0S et al (2017) Antimelanoma differentiation-associated gene 5 antibody: expanding the clinical spectrum in North American patients with dermatomyositis. J\u00a0Rheumatol 44(3):319\u2013325","journal-title":"J Rheumatol"},{"issue":"1","key":"1205_CR26","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13613-018-0433-3","volume":"8","author":"C Vuillard","year":"2018","unstructured":"Vuillard\u00a0C et al (2018) Clinical features and outcome of patients with acute respiratory failure revealing anti-synthetase or anti-MDA\u20115 dermato-pulmonary syndrome: a\u00a0French multicenter retrospective study. Ann Intensive Care 8(1):87","journal-title":"Ann Intensive Care"},{"issue":"4","key":"1205_CR27","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.semarthrit.2020.03.007","volume":"50","author":"F Romero-Bueno","year":"2020","unstructured":"Romero-Bueno\u00a0F et al (2020) Recommendations for the treatment of anti-melanoma differentiation-associated gene 5\u2011positive dermatomyositis-associated rapidly progressive interstitial lung disease. Semin Arthritis Rheum 50(4):776\u2013790","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"1205_CR28","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s00415-014-7623-1","volume":"262","author":"A Rosenbohm","year":"2015","unstructured":"Rosenbohm\u00a0A et\u00a0al (2015) Early diagnosis of cardiac involvement in idiopathic inflammatory myopathy by cardiac magnetic resonance tomography. J\u00a0Neurol 262(4):949\u2013956","journal-title":"J Neurol"},{"issue":"10","key":"1205_CR29","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1177\/000331979104201010","volume":"42","author":"TJ Byrnes","year":"1991","unstructured":"Byrnes\u00a0TJ, Baethge\u00a0BA, Wolf\u00a0RE (1991) Noninvasive cardiovascular studies in patients with inflammatory myopathy. Angiology 42(10):843\u2013848","journal-title":"Angiology"},{"issue":"4","key":"1205_CR30","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1097\/MNM.0000000000000981","volume":"40","author":"PG Maliha","year":"2019","unstructured":"Maliha\u00a0PG et al (2019) 18F-FDG PET\/CT versus conventional investigations for cancer screening in autoimmune inflammatory myopathy in the era of novel myopathy classifications. Nucl Med Commun 40(4):377\u2013382","journal-title":"Nucl Med Commun"},{"issue":"4","key":"1205_CR31","doi-asserted-by":"publisher","first-page":"e94128","DOI":"10.1371\/journal.pone.0094128","volume":"9","author":"X Lu","year":"2014","unstructured":"Lu\u00a0X et al (2014) Factors predicting malignancy in patients with polymyositis and dermatomyostis: a\u00a0systematic review and meta-analysis. PLoS ONE 9(4):e94128","journal-title":"PLoS ONE"},{"issue":"6","key":"1205_CR32","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.amjmed.2009.11.012","volume":"123","author":"A Selva-O\u2019Callaghan","year":"2010","unstructured":"Selva-O\u2019Callaghan\u00a0A et al (2010) Conventional cancer screening versus PET\/CT in dermatomyositis\/polymyositis. Am J Med 123(6):558\u2013562","journal-title":"Am J Med"},{"issue":"10","key":"1205_CR33","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1136\/ard.2006.068502","volume":"66","author":"H Chinoy","year":"2007","unstructured":"Chinoy\u00a0H et al (2007) The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis 66(10):1345\u20131349","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 11","key":"1205_CR34","doi-asserted-by":"publisher","first-page":"S118","DOI":"10.1002\/acr.20532","volume":"63","author":"LG Rider","year":"2011","unstructured":"Rider\u00a0LG et al (2011) Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: physician and patient\/parent global activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)\/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index\u20112 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI). Arthritis Care Res 63(Suppl 11):S118\u2013S157","journal-title":"Arthritis Care Res"},{"issue":"5","key":"1205_CR35","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/nrrheum.2018.33","volume":"14","author":"LG Rider","year":"2018","unstructured":"Rider\u00a0LG et\u00a0al (2018) Update on outcome assessment in myositis. Nat Rev Rheumatol 14(5):303\u2013318","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"1205_CR36","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/joim.12451","volume":"280","author":"Z Betteridge","year":"2016","unstructured":"Betteridge\u00a0Z, McHugh\u00a0N (2016) Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J\u00a0Intern Med 280(1):8\u201323","journal-title":"J Intern Med"},{"issue":"4","key":"1205_CR37","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.clindermatol.2018.04.008","volume":"36","author":"DM Tartar","year":"2018","unstructured":"Tartar\u00a0DM, Chung\u00a0L, Fiorentino\u00a0DF (2018) Clinical significance of autoantibodies in dermatomyositis and systemic sclerosis. Clin Dermatol 36(4):508\u2013524","journal-title":"Clin Dermatol"},{"issue":"12","key":"1205_CR38","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","volume":"76","author":"IE Lundberg","year":"2017","unstructured":"Lundberg\u00a0IE et\u00a0al (2017) 2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis 76(12):1955\u20131964","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1205_CR39","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.autrev.2018.10.004","volume":"18","author":"J Damoiseaux","year":"2019","unstructured":"Damoiseaux\u00a0J et al (2019) Autoantibodies in idiopathic inflammatory myopathies: clinical associations and laboratory evaluation by mono- and multispecific immunoassays. Autoimmun Rev 18(3):293\u2013305","journal-title":"Autoimmun Rev"},{"issue":"4","key":"1205_CR40","first-page":"548","volume":"30","author":"L Casciola-Rosen","year":"2012","unstructured":"Casciola-Rosen\u00a0L et al (2012) Isolated elevation of aldolase in the serum of myositis patients: a\u00a0potential biomarker of damaged early regenerating muscle cells. Clin Exp Rheumatol 30(4):548\u2013553","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"1205_CR41","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jbspin.2010.02.025","volume":"78","author":"RM Pereira","year":"2011","unstructured":"Pereira\u00a0RM, Freire de Carvalho\u00a0J (2011) Glucocorticoid-induced myopathy. Joint Bone Spine 78(1):41\u201344","journal-title":"Joint Bone Spine"},{"issue":"7","key":"1205_CR42","first-page":"1392","volume":"33","author":"MY Naim","year":"2006","unstructured":"Naim\u00a0MY, Reed\u00a0AM (2006) Enzyme elevation in patients with juvenile dermatomyositis and steroid myopathy. J\u00a0Rheumatol 33(7):1392\u20131394","journal-title":"J Rheumatol"},{"issue":"11","key":"1205_CR43","doi-asserted-by":"publisher","first-page":"e004262","DOI":"10.1161\/CIRCHEARTFAILURE.117.004262","volume":"10","author":"J Berg","year":"2017","unstructured":"Berg\u00a0J et al (2017) Cardiac magnetic resonance imaging in myocarditis reveals persistent disease activity despite normalization of cardiac enzymes and inflammatory parameters at 3\u2011month follow-up. Circ Heart Fail 10(11):e4262","journal-title":"Circ Heart Fail"},{"issue":"11","key":"1205_CR44","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s11926-015-0544-x","volume":"17","author":"B Maurer","year":"2015","unstructured":"Maurer\u00a0B, Walker\u00a0UA (2015) Role of MRI in diagnosis and management of idiopathic inflammatory myopathies. Curr Rheumatol Rep 17(11):67","journal-title":"Curr Rheumatol Rep"},{"issue":"2","key":"1205_CR45","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/mus.24307","volume":"51","author":"J Van De Vlekkert","year":"2015","unstructured":"Van De Vlekkert\u00a0J et al (2015) Combining MRI and muscle biopsy improves diagnostic accuracy in subacute-onset idiopathic inflammatory myopathy. Muscle Nerve 51(2):253\u2013258","journal-title":"Muscle Nerve"},{"key":"1205_CR46","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ijcard.2016.04.158","volume":"217","author":"SI Mavrogeni","year":"2016","unstructured":"Mavrogeni\u00a0SI et\u00a0al (2016) Cardiovascular magnetic resonance in rheumatology: current status and recommendations for use. Int J Cardiol 217:135\u2013148","journal-title":"Int J Cardiol"},{"issue":"3","key":"1205_CR47","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.ijcard.2010.08.013","volume":"148","author":"R Gupta","year":"2011","unstructured":"Gupta\u00a0R et\u00a0al (2011) Clinical cardiac involvement in idiopathic inflammatory myopathies: a\u00a0systematic review. Int J Cardiol 148(3):261\u2013270","journal-title":"Int J Cardiol"},{"issue":"3","key":"1205_CR48","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1111\/1756-185X.13257","volume":"21","author":"L Gupta","year":"2018","unstructured":"Gupta\u00a0L et\u00a0al (2018) Prevalence and predictors of asymptomatic vertebral fractures in inflammatory myositis. Int J Rheum Dis 21(3):725\u2013731","journal-title":"Int J Rheum Dis"},{"issue":"4","key":"1205_CR49","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.reuma.2011.10.012","volume":"8","author":"G Gutierrez-Gutierrez","year":"2012","unstructured":"Gutierrez-Gutierrez\u00a0G et al (2012) Use of electromyography in the diagnosis of inflammatory myopathies. Reumatol Clin 8(4):195\u2013200","journal-title":"Reumatol Clin"},{"issue":"11","key":"1205_CR50","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1093\/rheumatology\/kex226","volume":"56","author":"LG Rider","year":"2017","unstructured":"Rider\u00a0LG et al (2017) 2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects. Rheumatology 56(11):1884\u20131893","journal-title":"Rheumatology"},{"issue":"5","key":"1205_CR51","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.nmd.2004.02.006","volume":"14","author":"JE Hoogendijk","year":"2004","unstructured":"Hoogendijk\u00a0JE et\u00a0al (2004) 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10\u201312 October 2003, Naarden, The Netherlands. Neuromuscul Disord 14(5):337\u2013345","journal-title":"Neuromuscul Disord"},{"issue":"7","key":"1205_CR52","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1002\/art.22993","volume":"57","author":"L Miles","year":"2007","unstructured":"Miles\u00a0L et\u00a0al (2007) Predictability of the clinical course of juvenile dermatomyositis based on initial muscle biopsy: a\u00a0retrospective study of 72\u00a0patients. Arthritis Rheum 57(7):1183\u20131191","journal-title":"Arthritis Rheum"},{"issue":"10","key":"1205_CR53","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11926-015-0541-0","volume":"17","author":"EH Michelle","year":"2015","unstructured":"Michelle\u00a0EH, Mammen\u00a0AL (2015) Myositis mimics. Curr Rheumatol Rep 17(10):63","journal-title":"Curr Rheumatol Rep"},{"issue":"10019","key":"1205_CR54","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S0140-6736(15)01021-1","volume":"387","author":"N Ruperto","year":"2016","unstructured":"Ruperto\u00a0N et al (2016) Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a\u00a0randomised trial. Lancet 387(10019):671\u2013678","journal-title":"Lancet"},{"issue":"2","key":"1205_CR55","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1136\/annrheumdis-2016-209247","volume":"76","author":"F Bellutti Enders","year":"2017","unstructured":"Bellutti Enders\u00a0F et al (2017) Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis 76(2):329\u2013340","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1205_CR56","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1002\/art.40395","volume":"70","author":"S Ringold","year":"2018","unstructured":"Ringold\u00a0S et\u00a0al (2018) The Childhood Arthritis and Rheumatology Research Alliance consensus treatment plans: toward comparative effectiveness in the pediatric rheumatic diseases. Arthritis Rheumatol 70(5):669\u2013678","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"1205_CR57","doi-asserted-by":"publisher","first-page":"3570","DOI":"10.1002\/art.21378","volume":"52","author":"AV Ramanan","year":"2005","unstructured":"Ramanan\u00a0AV et\u00a0al (2005) The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. Arthritis Rheum 52(11):3570\u20133578","journal-title":"Arthritis Rheum"},{"issue":"12","key":"1205_CR58","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1136\/ard.2011.153718","volume":"70","author":"CG Lam","year":"2011","unstructured":"Lam\u00a0CG et\u00a0al (2011) Efficacy of intravenous Ig therapy in juvenile dermatomyositis. Ann Rheum Dis 70(12):2089\u20132094","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"1205_CR59","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1002\/acr.20269","volume":"62","author":"KA Rouster-Stevens","year":"2010","unstructured":"Rouster-Stevens\u00a0KA et al (2010) Mycophenolate mofetil: a\u00a0possible therapeutic agent for children with juvenile dermatomyositis. Arthritis Care Res 62(10):1446\u20131451","journal-title":"Arthritis Care Res"},{"issue":"7","key":"1205_CR60","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.3899\/jrheum.101321","volume":"38","author":"B Bader-Meunier","year":"2011","unstructured":"Bader-Meunier\u00a0B et al (2011) Safety and efficacy of rituximab in severe juvenile dermatomyositis: results from 9\u00a0patients from the French autoimmunity and rituximab registry. J\u00a0Rheumatol 38(7):1436\u20131440","journal-title":"J Rheumatol"},{"issue":"2","key":"1205_CR61","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s11926-020-00974-9","volume":"23","author":"O Kul Cinar","year":"2021","unstructured":"Kul Cinar\u00a0O, Papadopoulou\u00a0C, Pilkington\u00a0CA (2021) Treatment of calcinosis in juvenile dermatomyositis. Curr Rheumatol Rep 23(2):13","journal-title":"Curr Rheumatol Rep"},{"issue":"4","key":"1205_CR62","first-page":"441","volume":"17","author":"A Nzeusseu","year":"1999","unstructured":"Nzeusseu\u00a0A et al (1999) Functional outcome of myositis patients: Can a\u00a0low-dose glucocorticoid regimen achieve good functional results? Clin Exp Rheumatol 17(4):441\u2013446","journal-title":"Clin Exp Rheumatol"},{"issue":"8","key":"1205_CR63","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1136\/jnnp.57.8.1008","volume":"57","author":"S Matsubara","year":"1994","unstructured":"Matsubara\u00a0S et\u00a0al (1994) Pulsed intravenous methylprednisolone combined with oral steroids as the initial treatment of inflammatory myopathies. J\u00a0Neurol Neurosurg Psychiatry 57(8):1008","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"1205_CR64","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1159\/000249745","volume":"167","author":"T Yanagisawa","year":"1983","unstructured":"Yanagisawa\u00a0T et\u00a0al (1983) Methylprednisolone pulse therapy in dermatomyositis. Dermatologica 167(1):47\u201351","journal-title":"Dermatologica"},{"issue":"4","key":"1205_CR65","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/MJT.0000000000000175","volume":"22","author":"P Raghu","year":"2015","unstructured":"Raghu\u00a0P et\u00a0al (2015) Pulse dose methylprednisolone therapy for adult idiopathic inflammatory myopathy. Am J Ther 22(4):244\u2013247","journal-title":"Am J Ther"},{"issue":"6","key":"1205_CR66","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1093\/rheumatology\/keu442","volume":"54","author":"F Ibrahim","year":"2015","unstructured":"Ibrahim\u00a0F et al (2015) Second-line agents in myositis: 1\u2011year factorial trial of additional immunosuppression in patients who have partially responded to steroids. Rheumatology 54(6):1050\u20131055","journal-title":"Rheumatology"},{"issue":"2","key":"1205_CR67","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/00124743-199504000-00007","volume":"1","author":"ED Newman","year":"1995","unstructured":"Newman\u00a0ED, Scott\u00a0DW (1995) The use of low-dose oral methotrexate in the treatment of polymyositis and dermatomyositis. J\u00a0Clin Rheumatol 1(2):99\u2013102","journal-title":"J Clin Rheumatol"},{"issue":"5 Pt 1","key":"1205_CR68","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/0190-9622(95)91455-2","volume":"32","author":"ME Zieglschmid-Adams","year":"1995","unstructured":"Zieglschmid-Adams\u00a0ME et al (1995) Treatment of dermatomyositis with methotrexate. J\u00a0Am Acad Dermatol 32(5 Pt 1):754\u2013757","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1205_CR69","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1080\/030097400750001897","volume":"29","author":"J Vencovsky","year":"2000","unstructured":"Vencovsky\u00a0J et\u00a0al (2000) Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol 29(2):95\u2013102","journal-title":"Scand J Rheumatol"},{"issue":"2","key":"1205_CR70","first-page":"254","volume":"35","author":"T Kotani","year":"2008","unstructured":"Kotani\u00a0T et al (2008) Early intervention with corticosteroids and cyclosporin A and 2\u2011hour postdose blood concentration monitoring improves the prognosis of acute\/subacute interstitial pneumonia in dermatomyositis. J\u00a0Rheumatol 35(2):254\u2013259","journal-title":"J Rheumatol"},{"issue":"2","key":"1205_CR71","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3109\/s10165-007-0553-3","volume":"17","author":"K Takada","year":"2007","unstructured":"Takada\u00a0K, Kishi\u00a0J, Miyasaka\u00a0N (2007) Step-up versus primary intensive approach to the treatment of interstitial pneumonia associated with dermatomyositis\/polymyositis: a\u00a0retrospective study. Mod Rheumatol 17(2):123\u2013130","journal-title":"Mod Rheumatol"},{"issue":"1","key":"1205_CR72","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s00296-015-3328-8","volume":"36","author":"DJ Go","year":"2016","unstructured":"Go\u00a0DJ et al (2016) Survival benefit associated with early cyclosporine treatment for dermatomyositis-associated interstitial lung disease. Rheumatol Int 36(1):125\u2013131","journal-title":"Rheumatol Int"},{"issue":"1","key":"1205_CR73","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/rheumatology\/keu166","volume":"54","author":"T Kurita","year":"2015","unstructured":"Kurita\u00a0T et\u00a0al (2015) The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis. Rheumatology 54(1):39\u201344","journal-title":"Rheumatology"},{"issue":"11","key":"1205_CR74","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.3899\/jrheum.161217","volume":"44","author":"N Sharma","year":"2017","unstructured":"Sharma\u00a0N et al (2017) Myositis-associated interstitial lung disease: predictors of failure of conventional treatment and response to tacrolimus in a\u00a0US cohort. J\u00a0Rheumatol 44(11):1612\u20131618","journal-title":"J Rheumatol"},{"issue":"12","key":"1205_CR75","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1111\/1756-185X.12931","volume":"19","author":"KI Ueno","year":"2016","unstructured":"Ueno\u00a0KI et\u00a0al (2016) Advantage of administering tacrolimus for improving prognosis of patients with polymyositis and dermatomyositis. Int J Rheum Dis 19(12):1322\u20131330","journal-title":"Int J Rheum Dis"},{"key":"1205_CR76","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/1471-2474-13-228","volume":"13","author":"Y Shimojima","year":"2012","unstructured":"Shimojima\u00a0Y et\u00a0al (2012) Coadministration of tacrolimus with corticosteroid accelerates recovery in refractory patients with polymyositis\/ dermatomyositis: a\u00a0retrospective study. BMC Musculoskelet Disord 13:228","journal-title":"BMC Musculoskelet Disord"},{"issue":"4","key":"1205_CR77","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/resp.13978","volume":"26","author":"T Fujisawa","year":"2021","unstructured":"Fujisawa\u00a0T et al (2021) Prednisolone and tacrolimus versus prednisolone and cyclosporin A to treat polymyositis\/dermatomyositis-associated ILD: a randomized, open-label trial. Respirology 26(4):370\u2013377","journal-title":"Respirology"},{"issue":"5","key":"1205_CR78","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1093\/rheumatology\/kez394","volume":"59","author":"K Takada","year":"2020","unstructured":"Takada\u00a0K et al (2020) Impact of adding tacrolimus to initial treatment of interstitial pneumonitis in polymyositis\/dermatomyositis: a\u00a0single-arm clinical trial. Rheumatology 59(5):1084\u20131093","journal-title":"Rheumatology"},{"issue":"4","key":"1205_CR79","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/0002-9343(93)90148-I","volume":"94","author":"MM Joffe","year":"1993","unstructured":"Joffe\u00a0MM et\u00a0al (1993) Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a\u00a0comparison of their efficacy. Am J Med 94(4):379\u2013387","journal-title":"Am J Med"},{"issue":"3","key":"1205_CR80","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1002\/1529-0131(199803)41:3<392::AID-ART3>3.0.CO;2-X","volume":"41","author":"L Villalba","year":"1998","unstructured":"Villalba\u00a0L et\u00a0al (1998) Treatment of refractory myositis: a\u00a0randomized crossover study of two new cytotoxic regimens. Arthritis Rheum 41(3):392\u2013399","journal-title":"Arthritis Rheum"},{"issue":"3","key":"1205_CR81","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1093\/rheumatology\/keh499","volume":"44","author":"V Majithia","year":"2005","unstructured":"Majithia\u00a0V, Harisdangkul\u00a0V (2005) Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy. Rheumatology 44(3):386\u2013389","journal-title":"Rheumatology"},{"issue":"10","key":"1205_CR82","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1002\/acr.20212","volume":"62","author":"PA Morganroth","year":"2010","unstructured":"Morganroth\u00a0PA, Kreider\u00a0ME, Werth\u00a0VP (2010) Mycophenolate mofetil for interstitial lung disease in dermatomyositis. Arthritis Care Res 62(10):1496\u20131501","journal-title":"Arthritis Care Res"},{"issue":"3","key":"1205_CR83","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1093\/rheumatology\/kel336","volume":"46","author":"CN Pisoni","year":"2007","unstructured":"Pisoni\u00a0CN et\u00a0al (2007) Mycophenolate mofetil treatment in resistant myositis. Rheumatology 46(3):516\u2013518","journal-title":"Rheumatology"},{"issue":"2","key":"1205_CR84","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.jaad.2019.05.105","volume":"82","author":"R Waldman","year":"2020","unstructured":"Waldman\u00a0R, DeWane\u00a0ME, Lu\u00a0J (2020) Dermatomyositis: diagnosis and treatment. J\u00a0Am Acad Dermatol 82(2):283\u2013296","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1205_CR85","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1136\/annrheumdis-2012-202857","volume":"73","author":"M Zong","year":"2014","unstructured":"Zong\u00a0M et al (2014) Anakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers: a\u00a0mechanistic study with 12\u00a0months follow-up. Ann Rheum Dis 73(5):913\u2013920","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1205_CR86","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s00296-019-04467-6","volume":"40","author":"T Khoo","year":"2020","unstructured":"Khoo\u00a0T, Limaye\u00a0V (2020) Biologic therapy in the idiopathic inflammatory myopathies. Rheumatol Int 40(2):191\u2013205","journal-title":"Rheumatol Int"},{"issue":"3","key":"1205_CR87","doi-asserted-by":"publisher","first-page":"e14939","DOI":"10.1111\/dth.14939","volume":"34","author":"A Paudyal","year":"2021","unstructured":"Paudyal\u00a0A et al (2021) JAK-inhibitors for dermatomyositis: a concise literature review. Dermatol Ther 34(3):e14939","journal-title":"Dermatol Ther"},{"issue":"2","key":"1205_CR88","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1093\/rheumatology\/kew396","volume":"56","author":"R Aggarwal","year":"2017","unstructured":"Aggarwal\u00a0R et\u00a0al (2017) Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab. Rheumatology 56(2):247\u2013254","journal-title":"Rheumatology"},{"issue":"6","key":"1205_CR89","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1001\/archderm.143.6.763","volume":"143","author":"L Chung","year":"2007","unstructured":"Chung\u00a0L, Genovese\u00a0MC, Fiorentino\u00a0DF (2007) A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol 143(6):763\u2013767","journal-title":"Arch Dermatol"},{"issue":"2","key":"1205_CR90","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s10067-013-2449-2","volume":"34","author":"C Basnayake","year":"2015","unstructured":"Basnayake\u00a0C et\u00a0al (2015) Use of rituximab in histologically confirmed idiopathic inflammatory myositis: a\u00a0case series. Clin Rheumatol 34(2):371\u2013377","journal-title":"Clin Rheumatol"},{"issue":"6","key":"1205_CR91","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1007\/s10067-020-05530-5","volume":"40","author":"Y Ge","year":"2021","unstructured":"Ge\u00a0Y et al (2021) Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis responds to rituximab therapy. Clin Rheumatol 40(6):2311\u20132317","journal-title":"Clin Rheumatol"},{"issue":"2","key":"1205_CR92","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/art.37754","volume":"65","author":"CV Oddis","year":"2013","unstructured":"Oddis\u00a0CV et al (2013) Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a\u00a0randomized, placebo-phase trial. Arthritis Rheum 65(2):314\u2013324","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1205_CR93","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1093\/rheumatology\/kew146","volume":"56","author":"S Fasano","year":"2017","unstructured":"Fasano\u00a0S et\u00a0al (2017) Rituximab in the treatment of inflammatory myopathies: a\u00a0review. Rheumatology 56(1):26\u201336","journal-title":"Rheumatology"},{"issue":"27","key":"1205_CR94","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","volume":"329","author":"MC Dalakas","year":"1993","unstructured":"Dalakas\u00a0MC et al (1993) A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N\u00a0Engl J Med 329(27):1993\u20132000","journal-title":"N Engl J Med"},{"issue":"1","key":"1205_CR95","doi-asserted-by":"publisher","first-page":"e23677","DOI":"10.1097\/MD.0000000000023677","volume":"100","author":"R Aggarwal","year":"2021","unstructured":"Aggarwal\u00a0R et al (2021) Prospective, double-blind, randomized, placebo-controlled phase III study evaluating efficacy and safety of octagam 10\u202f% in patients with dermatomyositis (\u201cProDERM Study\u201d). Medicine 100(1):e23677","journal-title":"Medicine"},{"issue":"3","key":"1205_CR96","doi-asserted-by":"publisher","first-page":"382","DOI":"10.3109\/s10165-011-0534-4","volume":"22","author":"N Miyasaka","year":"2012","unstructured":"Miyasaka\u00a0N et al (2012) Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a\u00a0randomized double-blind placebo-controlled trial. Mod Rheumatol 22(3):382\u2013393","journal-title":"Mod Rheumatol"},{"issue":"2","key":"1205_CR97","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1002\/art.10053","volume":"46","author":"P Cherin","year":"2002","unstructured":"Cherin\u00a0P et al (2002) Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum 46(2):467\u2013474","journal-title":"Arthritis Rheum"},{"issue":"4","key":"1205_CR98","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3109\/s10165-003-0250-9","volume":"13","author":"M Hara","year":"2003","unstructured":"Hara\u00a0M et al (2003) Prospective study of high-dose intravenous immunoglobulin for the treatment of steroid-resistant polymyositis and dermatomyositis. Mod Rheumatol 13(4):319\u2013325","journal-title":"Mod Rheumatol"},{"issue":"4","key":"1205_CR99","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s10067-013-2478-x","volume":"33","author":"MG Danieli","year":"2014","unstructured":"Danieli\u00a0MG et al (2014) Open-label study on treatment with 20\u202f% subcutaneous IgG administration in polymyositis and dermatomyositis. Clin Rheumatol 33(4):531\u2013536","journal-title":"Clin Rheumatol"},{"issue":"3","key":"1205_CR100","first-page":"397","volume":"30","author":"EI Kampylafka","year":"2012","unstructured":"Kampylafka\u00a0EI et al (2012) The effect of intravenous immunoglobulin (IVIG) treatment on patients with dermatomyositis: a\u00a04-year follow-up study. Clin Exp Rheumatol 30(3):397\u2013401","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"1205_CR101","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1093\/rheumatology\/kel112","volume":"46","author":"Y Yamasaki","year":"2007","unstructured":"Yamasaki\u00a0Y et\u00a0al (2007) Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis\/dermatomyositis. Rheumatology 46(1):124\u2013130","journal-title":"Rheumatology"},{"issue":"9","key":"1205_CR102","first-page":"1719","volume":"32","author":"H Kameda","year":"2005","unstructured":"Kameda\u00a0H et\u00a0al (2005) Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute\/subacute interstitial pneumonia in patients with dermatomyositis. J\u00a0Rheumatol 32(9):1719\u20131726","journal-title":"J Rheumatol"},{"issue":"3","key":"1205_CR103","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/art.41105","volume":"72","author":"H Tsuji","year":"2020","unstructured":"Tsuji\u00a0H et al (2020) Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5\u2011positive dermatomyositis. Arthritis Rheumatol 72(3):488\u2013498","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"1205_CR104","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1007\/s00296-012-2653-4","volume":"33","author":"D Chen","year":"2013","unstructured":"Chen\u00a0D et\u00a0al (2013) Efficacy of infliximab in the treatment for dermatomyositis with acute interstitial pneumonia: a\u00a0study of fourteen cases and literature review. Rheumatol Int 33(10):2455\u20132458","journal-title":"Rheumatol Int"},{"issue":"9","key":"1205_CR105","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1136\/ard.2005.048744","volume":"65","author":"P Efthimiou","year":"2006","unstructured":"Efthimiou\u00a0P, Schwartzman\u00a0S, Kagen\u00a0LJ (2006) Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a\u00a0retrospective study of eight patients. Ann Rheum Dis 65(9):1233\u20131236","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1205_CR106","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/ana.22477","volume":"70","author":"Muscle Study Group","year":"2011","unstructured":"Muscle Study Group (2011) A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol 70(3):427\u2013436","journal-title":"Ann Neurol"},{"issue":"12","key":"1205_CR107","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1136\/ard.2007.077974","volume":"67","author":"M Dastmalchi","year":"2008","unstructured":"Dastmalchi\u00a0M et\u00a0al (2008) A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 67(12):1670\u20131677","journal-title":"Ann Rheum Dis"},{"issue":"3-4","key":"1205_CR108","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1159\/000114036","volume":"59","author":"GJ Hengstman","year":"2008","unstructured":"Hengstman\u00a0GJ et al (2008) Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate. Eur Neurol 59(3-4):159\u2013163","journal-title":"Eur Neurol"},{"issue":"9","key":"1205_CR109","first-page":"1802","volume":"33","author":"F Iannone","year":"2006","unstructured":"Iannone\u00a0F et\u00a0al (2006) Use of etanercept in the treatment of dermatomyositis: a\u00a0case series. J\u00a0Rheumatol 33(9):1802\u20131804","journal-title":"J Rheumatol"},{"key":"1205_CR110","doi-asserted-by":"publisher","first-page":"783416","DOI":"10.3389\/fmed.2021.783416","volume":"8","author":"K Tang","year":"2021","unstructured":"Tang\u00a0K, Zhang\u00a0H, Jin\u00a0H (2021) Clinical characteristics and management of patients with clinical amyopathic dermatomyositis: a retrospective study of 64 patients at a\u00a0tertiary dermatology department. Front Med 8:783416","journal-title":"Front Med"},{"issue":"18","key":"1205_CR111","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","volume":"381","author":"KR Flaherty","year":"2019","unstructured":"Flaherty\u00a0KR et\u00a0al (2019) Nintedanib in progressive fibrosing interstitial lung diseases. N\u00a0Engl J Med 381(18):1718\u20131727","journal-title":"N Engl J Med"},{"key":"1205_CR112","doi-asserted-by":"publisher","first-page":"626953","DOI":"10.3389\/fmed.2021.626953","volume":"8","author":"J Liang","year":"2021","unstructured":"Liang\u00a0J et al (2021) Efficacy and tolerability of nintedanib in idiopathic-inflammatory-myopathy-related interstitial lung disease: a pilot study. Front Med 8:626953","journal-title":"Front Med"},{"key":"1205_CR113","doi-asserted-by":"publisher","first-page":"33226","DOI":"10.1038\/srep33226","volume":"6","author":"T Li","year":"2016","unstructured":"Li\u00a0T et\u00a0al (2016) Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis. Sci Rep 6:33226","journal-title":"Sci Rep"},{"key":"1205_CR114","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s40674-021-00186-x","volume":"7","author":"A Selva-O\u2019Callaghan","year":"2021","unstructured":"Selva-O\u2019Callaghan\u00a0A et al (2021) Pharmacologic treatment of anti-MDA5 rapidly progressive interstitial lung disease. Curr Treatm Opt Rheumatol 7:319\u2013333","journal-title":"Curr Treatm Opt Rheumatol"},{"issue":"2","key":"1205_CR115","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.jaad.2019.07.006","volume":"82","author":"H Traineau","year":"2020","unstructured":"Traineau\u00a0H et\u00a0al (2020) Treatment of calcinosis cutis in systemic sclerosis and dermatomyositis: a review of the literature. J\u00a0Am Acad Dermatol 82(2):317\u2013325","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"1205_CR116","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1093\/rheumatology\/ker292","volume":"50","author":"GE Habers","year":"2011","unstructured":"Habers\u00a0GE, Takken\u00a0T (2011) Safety and efficacy of exercise training in patients with an idiopathic inflammatory myopathy\u2014a systematic review. Rheumatology 50(11):2113\u20132124","journal-title":"Rheumatology"},{"issue":"11","key":"1205_CR117","doi-asserted-by":"publisher","first-page":"3585","DOI":"10.1002\/art.23960","volume":"58","author":"E Stringer","year":"2008","unstructured":"Stringer\u00a0E, Singh-Grewal\u00a0D, Feldman\u00a0BM (2008) Predicting the course of juvenile dermatomyositis: significance of early clinical and laboratory features. Arthritis Rheum 58(11):3585\u20133592","journal-title":"Arthritis Rheum"},{"issue":"5","key":"1205_CR118","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1002\/art.20179","volume":"50","author":"AM Huber","year":"2004","unstructured":"Huber\u00a0AM et\u00a0al (2004) Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. Arthritis Rheum 50(5):1595\u20131603","journal-title":"Arthritis Rheum"},{"issue":"4","key":"1205_CR119","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1002\/art.24343","volume":"61","author":"MT Apaz","year":"2009","unstructured":"Apaz\u00a0MT et al (2009) Health-related quality of life of patients with juvenile dermatomyositis: results from the Pediatric Rheumatology International Trials Organisation multinational quality of life cohort study. Arthritis Rheum 61(4):509\u2013517","journal-title":"Arthritis Rheum"},{"issue":"7","key":"1205_CR120","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/acr.21637","volume":"64","author":"A Tollisen","year":"2012","unstructured":"Tollisen\u00a0A et al (2012) Quality of life in adults with juvenile-onset dermatomyositis: a\u00a0case-control study. Arthritis Care Res 64(7):1020\u20131027","journal-title":"Arthritis Care Res"},{"issue":"3","key":"1205_CR121","first-page":"333","volume":"24","author":"JC Wargula","year":"2006","unstructured":"Wargula\u00a0JC et\u00a0al (2006) What more can we learn from muscle histopathology in children with dermatomyositis\/polymyositis? Clin Exp Rheumatol 24(3):333\u2013343","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"1205_CR122","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/acr.20015","volume":"62","author":"A Ravelli","year":"2010","unstructured":"Ravelli\u00a0A et al (2010) Long-term outcome and prognostic factors of juvenile dermatomyositis: a\u00a0multinational, multicenter study of 490\u00a0patients. Arthritis Care Res 62(1):63\u201372","journal-title":"Arthritis Care Res"},{"issue":"2","key":"1205_CR123","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jpeds.2005.10.032","volume":"148","author":"LM Pachman","year":"2006","unstructured":"Pachman\u00a0LM et\u00a0al (2006) Duration of illness is an important variable for untreated children with juvenile dermatomyositis. J\u00a0Pediatr 148(2):247\u2013253","journal-title":"J Pediatr"},{"issue":"5","key":"1205_CR124","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1007\/s00415-014-7313-z","volume":"261","author":"J van de Vlekkert","year":"2014","unstructured":"van de Vlekkert\u00a0J, Hoogendijk\u00a0JE, de Visser\u00a0M (2014) Long-term follow-up of 62\u00a0patients with myositis. J\u00a0Neurol 261(5):992\u2013998","journal-title":"J Neurol"},{"issue":"3","key":"1205_CR125","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s11926-012-0249-3","volume":"14","author":"I Marie","year":"2012","unstructured":"Marie\u00a0I (2012) Morbidity and mortality in adult polymyositis and dermatomyositis. Curr Rheumatol Rep 14(3):275\u2013285","journal-title":"Curr Rheumatol Rep"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-022-01205-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-022-01205-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-022-01205-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T09:24:16Z","timestamp":1727083456000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-022-01205-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,29]]},"references-count":125,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["1205"],"URL":"https:\/\/doi.org\/10.1007\/s00393-022-01205-5","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,29]]},"assertion":[{"value":"17 March 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F.\u00a0Dressler und B.\u00a0Maurer geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patienten zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern eine schriftliche Einwilligung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}